By April 2020, a third of the world’s population was living under medical martial law. But there was a light at the end of the tunnel: trusted pharmaceutical companies were developing “safe and effective” vaccines that would stop the spread of the dreaded virus and end the pandemic. Or so we were told.
The clock was ticking – and Big Pharma needed lots of money in order to expedite the creation of a miracle drug. In the United States, the Trump administration launched Operation Warp Speed, a lavishly funded program that aimed to accelerate the development and distribution of coronavirus elixirs.
At the same time, the Russian government poured resources into developing its own vaccine. Funding for the public health initiative came from the Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund. In June 2020, RDIF announced a joint venture with R-Pharm, one of Russia’s largest pharmaceutical firms.
The duo would work together to produce and distribute a vaccine developed by the Russian health ministry’s Gamaleya Center.
The health ministry approved the vaccine after less than two months of testing, making Sputnik V the world’s first registered COVID shot. The drug’s catchy name was the brainchild of RDIF CEO Kirill Dmitriev, a World Economic Forum Young Global Leader (Class of 2009).
The Soros Foundation spotted Dmitriev’s potential at an early age, and awarded him a scholarship to study at Stanford University and later Harvard Business School. He worked for Goldman Sachs and McKinsey & Company before taking the reins at RDIF in 2011.
Dmitriev’s decision to include R-Pharm in RDIF’s investment portfolio was a shrewd move worthy of his Young Global Leader pedigree.
On July 17, 2020, AstraZeneca announced R-Pharm would become “one of the hubs for the production and supply of [its] vaccine to international markets.” Under the agreement, the British-Swedish pharmaceutical giant agreed to transfer its adenoviral vector to Russia. R-Pharm would then be tasked with “finishing” doses and shipping them abroad.
The company said in a press release:
AstraZeneca is confident that, together with R-Pharm, it will be able to supply millions of people with the vaccine in the most efficient way,”
In other words: by July 2020, the Russian government had positioned itself to profit from the production and distribution of two COVID vaccines: Sputnik V and AstraZeneca’s shot.
As vaccine-linked injuries and deaths continue to be documented around the world, some have portrayed Russia as a bulwark against Big Pharma’s murderous business model. As we will document below, nothing could be further from the truth.
Read More: Russia & AstraZeneca: “Vaccine” Collusion
